Case Study

Leveraging Immunotherapy Expertise to Exceed Customer Goals

Cancer Immunotherapy research concept 450x300

A private biologics company needed a specialized oncology CRO to manage its Phase I, multi-center study to evaluate the safety and pharmacokinetic (PK) profile of an immunotherapeutic drug in subjects with advanced solid tumors. The Senior Director of Clinical Operations was searching for an oncology-experienced clinical trial partner that could support protocol design and accelerate the start-up process to meet a quick First Patient In (FPI) milestone. Following a competitive review, the sponsor selected IQVIA Biotech based on our ability to deliver adaptive trial design, demonstrated extensive oncology expertise, flexibility and understanding of nuanced immunotherapy drug trials.

Every study has its unique set of challenges and, in this case, it was timing. The customer needed FPI of 60 days in order to meet an internal stakeholder commitment. Continue reading to learn how the IQVIA Biotech Investigator Strategy and Site Coordination (ISSC) team created a comprehensive  plan to manage the start-up process and meet the customer’s expectations.

access the Case Study!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader